[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629029":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":11,"centralContacts":43,"locations":49,"responsibleParty":67,"collaborators":11,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":11,"eligibilityCriteria":75,"healthyVolunteers":71,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":11,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":95,"whyStopped":11,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Ankara City Hospital Bilkent","OTHER",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"D1: Moderate-dose dexamethasone","EXPERIMENTAL",null,[13,14],"Procedure: TAP Block","Drug: moderate dose Dexamethasone",{"label":16,"type":10,"description":11,"interventionNames":17},"D2: High-dose dexamethasone",[13,18],"Drug: High dose dexamethasone",{"label":20,"type":21,"description":11,"interventionNames":22},"S: Control (normal saline)","PLACEBO_COMPARATOR",[23,13],"Other: Saline (0.9% NaCl)",[25,29,34,39],{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Saline (0.9% NaCl)","Intravenous normal saline 4 mL administered intraoperatively to S group",[20],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":11},"PROCEDURE","TAP Block","Oblique subcostal TAP block is administered to all groups",[9,16,20],{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":11},"DRUG","moderate dose Dexamethasone","Intravenous dexamethasone administered intraoperatively at 0.1 mg\u002Fkg (D1)",[9],{"type":35,"name":40,"description":41,"armGroupLabels":42,"otherNames":11},"High dose dexamethasone","Intravenous dexamethasone administered intraoperatively at 0.2 mg\u002Fkg (D2; maximum 20 mg).",[16],[44],{"name":45,"role":46,"phone":47,"phoneExt":11,"email":48},"GÜL ŞİRİN KOÇ, MD","CONTACT","00905057779798","glcintosun@gmail.com",[50],{"facility":51,"status":11,"city":52,"state":53,"zip":54,"country":55,"countryCode":11,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Ankara Bilkent City Hospital Department of Anesthesiology and Reanimation","Ankara","Çankaya","06800","Turkey (Türkiye)",{"type":57,"coordinates":58},"Point",[59,60],32.85427,39.91987,{"lat":60,"lon":59},[63],{"name":64,"role":46,"phone":65,"phoneExt":11,"email":66},"Şemsi Mustafa AKSOY, Study Director","00905056212081","drsmaksoy@gmail.com",{"type":68,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100629029","comparison-of-the-effects-of-moderate--and-high-dose-glucocorticoids-on-postoperative-recovery-100629029",false,"NCT07469332","Comparison of the Effects of Moderate- and High-Dose Glucocorticoids on Postoperative Recovery","Comparison of the Effects of Moderate- and High-Dose Glucocorticoid Administration on Postoperative Recovery: A Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* ASA physical status I-II\n* Scheduled for elective laparoscopic cholecystectomy\n* Undergoing general anesthesia\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Patients younger than 18 years or older than 65 years\n* Known allergy to dexamethasone\n* ASA physical status III or higher\n* Surgical procedures lasting longer than 120 minutes\n* Emergency surgeries\n* Pregnant or breastfeeding patients\n* Patients with coagulopathy or receiving anticoagulant therapy\n* Known allergy to local anesthetics\n* Localized infection at the injection site\n* Inflammatory bowel disease\n* Autoimmune diseses\n* Chronic pain conditions\n* Ocular herpes simplex infection\n* Cushing's disease\n* Myasthenia gravis\n* Anticipated poor compliance with the study protocol\n* Vaccination within the last 14 days\n* Use of systemic glucocorticoids or immunosuppressive drugs\n* İmpaired renal function (GFR \\\u003C 30 mL\u002Fmin)\n* Liver cirrhosis\n* Congestive heart failure\n* Peripheral nerve disorders\n* Elective laparoscopic cholecystectomy due to malignancy\n* Conversion to open surgery during the operation\n* Epilepsy\n* Body mass index (BMI) \\> 30 kg\u002Fm²","ALL","18 Years","65 Years",{"count":80,"type":81},135,"ESTIMATED","INTERVENTIONAL",[84],"NA","Laparoscopic cholecystectomy is a commonly performed minimally invasive surgical procedure; however, postoperative pain, nausea, and delayed recovery remain clinically relevant problems. Glucocorticoids such as dexamethasone are widely used in perioperative care for the prevention of postoperative nausea and vomiting and as part of multimodal analgesia strategies.\n\nThis prospective randomized controlled trial aims to compare the effects of moderate- and high-dose intravenous dexamethasone administered intraoperatively on postoperative recovery in patients undergoing elective laparoscopic cholecystectomy. The primary outcomes include postoperative nausea and vomiting, inflammatory markers (CRP and WBC), and Quality of Recovery-15 (QoR-15) scores. Secondary outcomes include postoperative pain scores, intraoperative remifentanil consumption, postoperative opioid consumption, and adverse events.",[87,88],"Postoperative Recovery","PONV",[87,90,91,92,93,94],"Postoperative Pain","dexamethasone","Postoperative Nausea and Vomiting","high dose","moderate dose","NOT_YET_RECRUITING","2026-03-09",{"date":98,"type":99},"2026-03-13","ACTUAL",{"date":101,"type":81},"2026-03-30",{"date":103,"type":81},"2026-07-30",{"name":5,"class":6},1]